Antibe Therapeutics Inc. will be front-and-centre at the 4th International Conference on the Biology of Hydrogen Sulfide, to be held in Naples, Italy from June 3rd to 5th. The company’s founder and Chief Scientific Officer, John Wallace, and Antibe Scientific Advisor and Nobel Prize winner Louis Ignarro, will be making podium presentations at the conference. A distinguished collaborator, University of Naples cancer researcher Professor Angela Ianaro, will present a lecture on the potential for treating and preventing melanoma with hydrogen sulfide, using drugs like ATB-346, Antibe’s most advanced clinical candidate currently in a Phase 2 trial in osteoarthritis patients.
Dr. Wallace’s presentation will include evidence that has been gathered in recent months that clearly demonstrates that ATB-346 has much greater anti-inflammatory potency and duration-of-action in humans than had been observed in animal studies. ATB-346 has been administered to over 80 human subjects, with blood samples collected from all. Samples have been analyzed to measure levels of ATB-346 and its metabolites (break-down products) and to determine the effectiveness of the drug at blocking release of chemical mediators that produce pain and other symptoms of inflammation. Dr. Wallace remarked “we have strong evidence that ATB-346 is on the order of 6-times more potent than naproxen, with anti-inflammatory effects extending for 24 hours after a single dose. These data also provide an explanation for the signals of liver cell damage in some subjects in our Phase 1 study, where ATB-346 was given at very high doses and, in some cases, more than once-a-day.”
Professor Ianaro will give a lecture on “Involvement of hydrogen sulfide pathway in human melanoma development and progression”. Her studies have demonstrated that mice with melanomas respond very well to treatment with ATB-346. She observed rapid and profound reductions of tumour size and weight, and markedly reduced tumour cell proliferation.
In Antibe’s ongoing Phase 2 clinical trial of ATB-346, patients with osteoarthritis of the knee are receiving ATB-346 once daily over a period of 10 days. Osteoarthritis patients treated with naproxen generally take 4 tablets per day. In the clinical trial, ATB-346 is being administered at a dose equivalent to about one-half a naproxen tablet per day. The main end-point in the study is the degree of reduction of pain. The trial is on schedule, with an anticipated completion date in Q3.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (Citagenix), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry. Citagenix Inc. is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, failure to satisfy closing conditions for the transactions, not obtaining future financing on adequate terms, or at all, failure to obtain TSX Venture Exchange approval for the transactions described herein, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Antibe Therapeutics Inc.
Dan Legault, (416) 473-4095
Chief Executive Officer
Source : businesswire.com